AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31103129 — intervention group
Group type: COMPARATOR
Intervention: Placebo thoracic spine self-mobilization
Number of subjects: 52
Study 28735778 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga classes led by a certified instructor twice weekly for 12 weeks, with home practice.
Number of subjects: 150
Study 28735778 — intervention group
Group type: COMPARATOR
Intervention: Delayed yoga treatment (control group).
Number of subjects: 150
Study 28735778 — intervention group
Group type: COMPARATOR
Intervention: Both groups (yoga and control).
Number of subjects: 150
Study 26423915 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (alert in medical files and letters to patients and providers)
Number of subjects: 411
Study 26423915 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 411
Study 26423915 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 411
Study 25445079 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure (PE) for PTSD plus BRENDA
Number of subjects: 137
Study 25445079 — intervention group
Group type: COMPARATOR
Intervention: BRENDA alone
Number of subjects: 137
Study 25445079 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NAL) for AD
Number of subjects: 137
Study 25445079 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) for AD
Number of subjects: 137
Study 22971118 — intervention group
Group type: EXPERIMENTAL
Intervention: Aura‐i
Number of subjects: 120
Study 22971118 — intervention group
Group type: COMPARATOR
Intervention: air‐Q
Number of subjects: 120
Study 22971118 — intervention group
Group type: COMPARATOR
Intervention: air‐Q (Group 1)
Number of subjects: 120
Study 22971118 — intervention group
Group type: EXPERIMENTAL
Intervention: Aura‐i (Group 1)
Number of subjects: 120
Study 22971118 — intervention group
Group type: EXPERIMENTAL
Intervention: Aura‐i and air‐Q
Number of subjects: 120
Study 19778775 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stent (BES)
Number of subjects: 1707
Study 19778775 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 1707
Study 17868436 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercise Program (CSEP)
Number of subjects: 0
Study 17868436 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial Education Program (PSEP)
Number of subjects: 0
Study 17868436 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercise Program with Psychosocial Education (CSEP + PSEP)
Number of subjects: 0
Study 17868436 — intervention group
Group type: COMPARATOR
Intervention: Traditional Exercise Program (TEP)
Number of subjects: 0
Study 17868436 — intervention group
Group type: COMPARATOR
Intervention: Traditional Exercise Program with Psychosocial Education (TEP + PSEP)
Number of subjects: 0
Study 15221063 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (tailored resection, including microsurgical lesionectomy, lesionectomy plus cortectomy, and hippocampectomy)
Number of subjects: 30
Study 15221063 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampectomy
Number of subjects: 30
Study 15221063 — intervention group
Group type: EXPERIMENTAL
Intervention: Early operation after seizure manifestation (within 2 years)
Number of subjects: 30
Study 15221063 — intervention group
Group type: EXPERIMENTAL
Intervention: Unifocal seizure onset
Number of subjects: 30
Study 15221063 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection of one lesion in patients with multiple cavernomas
Number of subjects: 30
Study 11233456 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 635
Study 11233456 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 635
Study 11233456 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 635
Study 11233456 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sertraline and imipramine
Number of subjects: 635
Study 9374947 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg once-a-day
Number of subjects: 198
Study 9374947 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem slow release formulation (SR) 90 mg twice daily
Number of subjects: 198
Study 1556489 — intervention group
Group type: EXPERIMENTAL
Intervention: Three fractions per week radiotherapy
Number of subjects: 734
Study 1556489 — intervention group
Group type: COMPARATOR
Intervention: Five fractions per week radiotherapy
Number of subjects: 734
Study 1556489 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage laryngectomy after local recurrence
Number of subjects: 734
Study 1556489 — intervention group
Group type: EXPERIMENTAL
Intervention: Local recurrence
Number of subjects: 734
Study 3890575 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 40
Study 3890575 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 40
Study 3890575 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine plus primaquine
Number of subjects: 40
Study 31229466 — intervention group
Group type: EXPERIMENTAL
Intervention: Netarsudil/Latanoprost FDC
Number of subjects: 0
Study 31229466 — intervention group
Group type: COMPARATOR
Intervention: Netarsudil 0.02%
Number of subjects: 0
Study 31229466 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 0
Study 29562151 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow oxygen therapy
Number of subjects: 1472
Study 29562151 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 1472
Study 27169634 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus helveticus R0052 and Lactobacillus rhamnosus R0011, 8×10^9 CFU daily)
Number of subjects: 160
Study 27169634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 24028316 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminders
Number of subjects: 42
Study 24028316 — intervention group
Group type: COMPARATOR
Intervention: Control group (no text message reminders)
Number of subjects: 42
Study 22245954 — intervention group
Group type: EXPERIMENTAL
Intervention: aprepitant
Number of subjects: 18
Study 22245954 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 22245954 — intervention group
Group type: EXPERIMENTAL
Intervention: race
Number of subjects: 18
Study 19796883 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 0
Study 17631061 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 244
Study 17631061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 15716696 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ramipril
Number of subjects: 30
Study 15716696 — intervention group
Group type: COMPARATOR
Intervention: 100 mg atenolol
Number of subjects: 30
Study 15716696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12061475 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated discharge and home-based rehabilitation (n = 34)
Number of subjects: 66
Study 12061475 — intervention group
Group type: COMPARATOR
Intervention: Conventional hospital care (n = 32)
Number of subjects: 66
Study 10048741 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (flexible sigmoidoscopy)
Number of subjects: 400
Study 10048741 — intervention group
Group type: COMPARATOR
Intervention: Control group (not attending screening)
Number of subjects: 400
Study 8700764 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-setting amalgam
Number of subjects: 23
Study 8700764 — intervention group
Group type: COMPARATOR
Intervention: Slow-setting amalgam
Number of subjects: 23
Study 1887967 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 1.2 mg and Neostigmine 2.5 mg
Number of subjects: 22
Study 1887967 — intervention group
Group type: COMPARATOR
Intervention: Atropine 0.6 mg and Edrophonium 1 mg/kg
Number of subjects: 22
Study 6342748 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus vincristine, dactinomycin, and cyclophosphamide, with or without Adriamycin
Number of subjects: 24
Study 31586486 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g test rice
Number of subjects: 45
Study 31586486 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g test rice
Number of subjects: 45
Study 31586486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 31187048 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib cream (0.5%, 1.0%, 2.0%, and 4.0%) applied twice daily for 4 weeks
Number of subjects: 41
Study 31187048 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib cream (2.0% concentration)
Number of subjects: 41
Study 31187048 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 41
Study 29796741 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary closure (Group A)
Number of subjects: 60
Study 29796741 — intervention group
Group type: COMPARATOR
Intervention: Secondary closure (Group B)
Number of subjects: 60
Study 29796741 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 28116167 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised cognitive rehabilitation using RehaCom software, 45 minutes, three times weekly for six weeks.
Number of subjects: 38
Study 28116167 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no specific details provided).
Number of subjects: 38
Study 28116167 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised cognitive rehabilitation group.
Number of subjects: 38
Study 24193372 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg reboxetine (RBX) administered immediately after extinction learning
Number of subjects: 0
Study 24193372 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 0
Study 24193372 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RBX and PLC groups
Number of subjects: 0
Study 21879340 — intervention group
Group type: EXPERIMENTAL
Intervention: Fact sheet describing HPV vaccine as preventing cervical cancer only (n=81)
Number of subjects: 159
Study 21879340 — intervention group
Group type: EXPERIMENTAL
Intervention: Fact sheet describing HPV vaccine as preventing both cervical cancer and genital warts (n=78)
Number of subjects: 159
Study 21879340 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional TPB components
Number of subjects: 159
Study 21879340 — intervention group
Group type: EXPERIMENTAL
Intervention: Moral norm
Number of subjects: 159
Study 21879340 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination intention
Number of subjects: 159
Study 20920820 — intervention group
Group type: EXPERIMENTAL
Intervention: r-HGH replacement therapy for 6 months
Number of subjects: 60
Study 16971899 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg citalopram
Number of subjects: 18
Study 16971899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 15882785 — intervention group
Group type: EXPERIMENTAL
Intervention: Judoists (head upright vs tilted)
Number of subjects: 12
Study 15882785 — intervention group
Group type: EXPERIMENTAL
Intervention: Dancers (head upright vs tilted)
Number of subjects: 12
Study 15882785 — intervention group
Group type: EXPERIMENTAL
Intervention: Untrained participants (head upright vs tilted)
Number of subjects: 12
Study 15882785 — intervention group
Group type: EXPERIMENTAL
Intervention: VFI participants (experts and untrained)
Number of subjects: 12
Study 15882785 — intervention group
Group type: EXPERIMENTAL
Intervention: VFD participants (experts)
Number of subjects: 12
Study 15882785 — intervention group
Group type: EXPERIMENTAL
Intervention: VFD participants (untrained)
Number of subjects: 12
Study 12109715 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltamethrin-treated sheets
Number of subjects: 88
Study 12109715 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated sheets
Number of subjects: 88
Study 12109715 — intervention group
Group type: EXPERIMENTAL
Intervention: Alphacypermethrin-treated sheets
Number of subjects: 88
Study 12109715 — intervention group
Group type: COMPARATOR
Intervention: Untreated sheets (placebo)
Number of subjects: 88
Study 9678313 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic drugs
Number of subjects: 147
Study 9678313 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines (primarily clonazepam)
Number of subjects: 147
Study 9678313 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects of drug trials
Number of subjects: 147
Study 8083270 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteotomy
Number of subjects: 100
Study 8083270 — intervention group
Group type: COMPARATOR
Intervention: Anatomical reduction with AO dynamic hip screw
Number of subjects: 100
Study 2646357 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 58
Study 2646357 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid
Number of subjects: 58
Study 2646357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 30946478 — intervention group
Group type: EXPERIMENTAL
Intervention: App A (selected based on users' needs)
Number of subjects: 61
Study 30946478 — intervention group
Group type: COMPARATOR
Intervention: App B (app with the highest number of users worldwide)
Number of subjects: 61
Study 26607361 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous regadenoson 100 μg (3 doses)
Number of subjects: 36
Study 26607361 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous regadenoson 200 μg (3 doses)
Number of subjects: 36
Study 26607361 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous regadenoson 400 μg (2 doses)
Number of subjects: 36
Study 26607361 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride, 2 or 3 doses)
Number of subjects: 36
Study 25984779 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocoagulation
Number of subjects: 65
Study 25984779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scalpel (Ultracision)
Number of subjects: 65
Study 25984779 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency dissector (LigaSure)
Number of subjects: 65
Study 22329914 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK233705 200 µg
Number of subjects: 576
Study 22329914 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK233705 12.5 µg, 25 µg, 50 µg, 100 µg
Number of subjects: 576
Study 22329914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 576
Study 20939213 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 intracervical gel 0.5 mg (maximum of 3 doses, every 6 hours)
Number of subjects: 50
Study 20939213 — intervention group
Group type: COMPARATOR
Intervention: Vaginal insert of PGE2 (single dose for 24 hours)
Number of subjects: 50
Study 18292959 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotic prophylaxis with a single 400‐mg dose of norfloxacin
Number of subjects: 262
Study 18292959 — intervention group
Group type: COMPARATOR
Intervention: Placebo (norfloxacin placebo)
Number of subjects: 262
Study 16104905 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone cream 0.1% applied locally to neurovascular bundles (NVBs)
Number of subjects: 60
Study 16104905 — intervention group
Group type: COMPARATOR
Intervention: Usual BNS-RRP with no corticoid cream
Number of subjects: 60
Study 11796177 — intervention group
Group type: EXPERIMENTAL
Intervention: captopril 37.5 mg
Number of subjects: 79
Study 11796177 — intervention group
Group type: EXPERIMENTAL
Intervention: imidapril 5 mg
Number of subjects: 79
Study 11796177 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 79
Study 10067997 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with a tourniquet
Number of subjects: 77
Study 10067997 — intervention group
Group type: COMPARATOR
Intervention: Surgery without a tourniquet
Number of subjects: 77
Study 7486076 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 90
Study 7486076 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 90
Study 2178381 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 40 mg once daily
Number of subjects: 92
Study 2178381 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 40 mg 4 times daily
Number of subjects: 92
Study 2178381 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Betaxolol and Propranolol
Number of subjects: 92
Study 6106099 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide (PPS) vaccine given before radiation and chemotherapy
Number of subjects: 0
Study 6106099 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide (PPS) vaccine given before splenectomy
Number of subjects: 0
Study 31455832 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (post‐tetanic counts of 1‐2)
Number of subjects: 88
Study 31455832 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade (train‐of‐four counts of 1‐2)
Number of subjects: 88
Study 31455832 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade
Number of subjects: 88
Study 31455832 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade
Number of subjects: 88
Study 30408073 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week school-based physical activity intervention
Number of subjects: 663
Study 30408073 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 663
Study 30408073 — intervention group
Group type: EXPERIMENTAL
Intervention: Physically active and fit children
Number of subjects: 663
Study 26592732 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegAsp (insulin degludec/insulin aspart co-formulation)
Number of subjects: 274
Study 26592732 — intervention group
Group type: COMPARATOR
Intervention: IDeg+IAsp (basal insulin degludec once daily and prandial insulin aspart 2-4 times daily)
Number of subjects: 274
Study 26592732 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegAsp
Number of subjects: 274
Study 24831447 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline VL <10,000 copies/ml (N = 314)
Number of subjects: 1106
Study 24831447 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline VL 10,001-100,000 copies/ml (N = 338)
Number of subjects: 1106
Study 24831447 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline VL >100,000 copies/ml (N = 122)
Number of subjects: 1106
Study 22575768 — intervention group
Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Number of subjects: 52
Study 22575768 — intervention group
Group type: EXPERIMENTAL
Intervention: lifestyle behaviour change
Number of subjects: 52
Study 20632065 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented rTKA with a 100‐mm press‐fit stem
Number of subjects: 16
Study 18753646 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (6-g bolus followed by 2 g per hour infusion)
Number of subjects: 2241
Study 18753646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2241
Study 16370790 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentalization-based intervention
Number of subjects: 9
Study 16370790 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 9
Study 12238954 — intervention group
Group type: EXPERIMENTAL
Intervention: Use death from cancer as the primary endpoint
Number of subjects: 0
Study 12238954 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal estimate to adjust for nonattendance and contamination
Number of subjects: 0
Study 12238954 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive estimate to adjust for dilution in follow-up
Number of subjects: 0
Study 10604408 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensification regimen 2 including perioperative hyperfractionated radiotherapy (9.1 Gy), cisplatin (30 mg/m2 per day), surgical resection with intraoperative radiotherapy boost (7.5 Gy), postoperative radiotherapy (40 Gy to primary site and upper neck, 45 Gy to supraclavicular areas), paclitaxel (135 mg/m2 per 24 hours), and cisplatin (100 mg/m2).
Number of subjects: 43
Study 7542992 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 30
Study 7542992 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 20 mg
Number of subjects: 30
Study 7542992 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg/day
Number of subjects: 30
Study 2117846 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nitroglycerin therapy
Number of subjects: 0
Study 2117846 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent therapy with nitrate-free interval
Number of subjects: 0
Study 7253081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 110
Study 7253081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 31288028 — intervention group
Group type: EXPERIMENTAL
Intervention: SIC-8000
Number of subjects: 158
Study 31288028 — intervention group
Group type: COMPARATOR
Intervention: hetastarch
Number of subjects: 158
Study 27550959 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel daily for 14 weeks
Number of subjects: 62
Study 27550959 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel daily for 14 weeks
Number of subjects: 62
Study 24286198 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior 180° fundoplication
Number of subjects: 47
Study 24286198 — intervention group
Group type: COMPARATOR
Intervention: Posterior 270° fundoplication
Number of subjects: 47
Study 24500661 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol Group
Number of subjects: 66
Study 24500661 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane Group
Number of subjects: 66
Study 22210007 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg once daily for 5 days
Number of subjects: 24
Study 19056603 — intervention group
Group type: EXPERIMENTAL
Intervention: TV with food and nonfood ads (TV-ads)
Number of subjects: 48
Study 19056603 — intervention group
Group type: EXPERIMENTAL
Intervention: TV with no ads (TV-no ads)
Number of subjects: 48
Study 19056603 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 19056603 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading
Number of subjects: 48
Study 17580194 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based exercise program (n = 15)
Number of subjects: 38